ストックスクリーナーアプリを入手
5.93
4.77%
0.27
前日終値:
$5.66
開ける：
$5.73
24時間の取引高:
794.41K
Relative Volume:
0.51
時価総額：
$461.76M
収益：
$14.79M
当期純損益:
$-102.44M
株価収益率:
-1.9507
EPS:
-3.04
ネットキャッシュフロー:
$-91.73M
1週間 パフォーマンス:
-2.95%
1か月 パフォーマンス:
-4.82%
6か月 パフォーマンス:
+2.60%
1年 パフォーマンス:
-37.18%
1日の値動き範囲:
$5.655
$6.07
1週間の範囲:
$5.4617
$6.28
52週間の値動き範囲:
$2.41
$10.07
Solid Biosciences Inc Stock (SLDB) Company Profile
名前
Solid Biosciences Inc
セクター
電話
617-337-4680
住所
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.93 | 469.55M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-26 | 開始されました | Citigroup | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-13 | 開始されました | Wedbush | Outperform |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-15 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-06-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | William Blair | Outperform |
| 2024-03-15 | 開始されました | Citigroup | Buy |
| 2024-03-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | Piper Sandler | Neutral |
| 2021-05-27 | 開始されました | Jefferies | Buy |
| 2021-03-16 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2021-01-08 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 開始されました | Evercore ISI | Outperform |
| 2019-08-29 | ダウングレード | Citigroup | Neutral → Sell |
| 2019-08-19 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | ダウングレード | Goldman | Neutral → Sell |
| 2019-02-08 | アップグレード | Citigroup | Sell → Neutral |
| 2019-02-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 開始されました | Citigroup | Sell |
| 2018-09-06 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Solid Biosciences Inc (SLDB) 最新ニュース
What institutions are buying Solid Biosciences Inc. stock nowJuly 2025 Catalysts & High Accuracy Buy Signal Tips - beatles.ru
Solid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street Zen - MarketBeat
Solid Biosciences Inc. Stages Intraday Comeback — Trend ChangeQuarterly Profit Review & Weekly Market Pulse Updates - sundaytimes.kr
Is Solid Biosciences Inc. stock a value trapAnalyst Upgrade & Long Hold Capital Preservation Tips - mustnews.co.kr
Wyckoff Accumulation Phase Possible in Solid Biosciences Inc.2025 Valuation Update & Expert Curated Trade Setups - metal.it
Is Solid Biosciences Inc. stock a good pick for beginnersJuly 2025 Market Mood & Weekly Return Optimization Alerts - thegnnews.com
Why Solid Biosciences Inc. stock attracts strong analyst attentionJuly 2025 Spike Watch & Fast Entry High Yield Stock Tips - beatles.ru
Is now the right time to enter Solid Biosciences Inc.Market Growth Summary & AI Powered Trade Plan Recommendations - sundaytimes.kr
Solid Biosciences Reports Increased Assets Amid Ongoing Losses - MSN
Solid Biosciences Inc. shares fall 1.05% intraday as Tyra Biosciences reports financial results and clinical progress. - AInvest
Solid Biosciences Gains Momentum with Promising DMD Program and Strategic Expansion - TipRanks
Solid Biosciences’ SWOT analysis: promising DMD gene therapy stock faces pivotal year - Investing.com
Citi Maintains Buy Rating on Solid Biosciences with $16 Price Target - AInvest
Citizens JMP Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
J.P. Morgan Sticks to Their Buy Rating for Solid Biosciences (SLDB) - The Globe and Mail
SLDB’s Stock Market Adventure: -9.49% YTD Growth Amidst Volatility - investchronicle.com
JMP reiterates Market Outperform rating on Solid Biosciences stock By Investing.com - Investing.com Canada
Can Solid Biosciences Inc. recover in the next quarter2025 Growth vs Value & Weekly Market Pulse Updates - Newser
40,930 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Purchased by XTX Topco Ltd - Defense World
Solid Biosciences (NASDAQ:SLDB) Shares Up 9.9% Following Strong Earnings - Defense World
Smart tools for monitoring Solid Biosciences Inc.’s price actionWeekly Volume Report & Weekly High Conviction Ideas - Newser
Is Solid Biosciences Inc. stock overhyped or has real potentialOptions Play & Real-Time Market Sentiment Alerts - Newser
Developing predictive dashboards with Solid Biosciences Inc. data2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Wedbush Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $14 - 富途牛牛
William Blair Maintains Buy Rating for Solid Biosciences, Raises Price Target to $15.44. - AInvest
A Quick Look at Today's Ratings for Solid Biosciences(SLDB.US), With a Forecast Between $10 to $20 - 富途牛牛
Solid Biosciences: Promising Developments and Financial Stability Drive Buy Rating - TipRanks
Solid Biosciences Raises up to $50 Million in Series C Financing - Bain Capital
How Solid Biosciences Inc. stock performs during market volatilitySecure Entry Point Finder with Analysis - Newser
Solid Biosciences shares rise 2.81% after-hours following Anixa Biosciences' patent extension to 2045. - AInvest
SOLID BIOSCIENCES Earnings Results: $SLDB Reports Quarterly Earnings - Quiver Quantitative
Solid Biosciences Pushes Forward Despite Growing Losses - Finimize
Solid Biosciences reports Q2 EPS (42c), consensus (49c) - TipRanks
Solid Biosciences Q2 net loss widens to $39.5 mln - MarketScreener
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences Inc. Reports Progress in Clinical Trials and Financial Highlights for Q2 2025 - Quiver Quantitative
How to read the order book for Solid Biosciences Inc.Market Forecast Summary Over Multi-Year Period - Newser
Applying big data sentiment scoring on Solid Biosciences Inc.Momentum Prediction Based on AI Backtesting - Newser
Risk adjusted return profile for Solid Biosciences Inc. analyzedStock Market Watch with Smart Filters - Newser
Solid Biosciences Inc. stock trend forecastFree Earnings Play Trade Plan With Alerts - Newser
Key resistance and support levels for Solid Biosciences Inc.Volume Confirmed Setup with Entry Confidence - Newser
Solid Biosciences (SLDB) Projected to Post Quarterly Earnings on Tuesday - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Analysts - Defense World
Solid Biosciences SLDB 2025Q2 Earnings Preview Upside Potential on Strategic Developments - AInvest
Will Solid Biosciences Inc. rebound enough to break evenPrice Movement and Market Sentiment Analysis - Newser
Applying Elliott Wave Theory to Solid Biosciences Inc.Chart Pattern Recognition for Profit Timing - Newser
Solid Biosciences Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
How hedge fund analytics apply to Solid Biosciences Inc. stockSwing Entry Risk Mitigation with Chart Analysis - Newser
Allianz Asset Management GmbH Purchases Shares of 27,100 Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Inc. shares rise 1.03% after-hours following Wall Street's recovery from jobs report-fueled losses. - AInvest
What is the dividend policy of Solid Biosciences Inc. stockGet timely alerts on market opportunities - Jammu Links News
Solid Biosciences Inc (SLDB) 財務データ
収益
当期純利益
現金流量
EPS
Solid Biosciences Inc (SLDB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):